Chargement en cours...
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab remains to date the only targeted therapy approved for the treatment of head and neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the tumorigenesis and progression of this disease as well as in the resistance to radiotherapy (RT). While several anti-EGFR agents ha...
Enregistré dans:
| Publié dans: | Front Oncol |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536039/ https://ncbi.nlm.nih.gov/pubmed/31165040 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00383 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|